This clinical trial is evaluating an investigational vaccine designed to prevent chlamydia infections, a common sexually transmitted infection that often goes undetected due to lack of symptoms. The study aims to determine the safety, immune response, and effectiveness of the vaccine in adults aged 18 to 29 by administering either the investigational vaccine or a placebo at a 1:1 ratio. The study is blinded, meaning participants will not know which study group they are in during their participation to avoid bias.
Each participant will receive 3 doses for this study, given at Day 1, Month 2, and Month 6.
Study participation is approximately 18 months and includes up to 13 in-person visits (Mon–Fri, 9am–5pm) and up to 4 phone calls. Procedures may include medical history, physical exam and vital signs, ECGs, blood tests, pregnancy tests, urine tests, swab collections, and an eDiary.
You will be paid $3,500 for your participation.
